Hearing Restored: Gene Therapy Breakthrough for Genetic Deafness
A gene therapy treatment for a rare form of genetic deafness has demonstrated sustained hearing restoration in clinical trials, and a related therapy has received approval from the U.S. Food and Drug Administration (FDA). The treatment is designed for patients with autosomal recessive deafness 9 (DFNB9), a condition caused by mutations in the OTOF gene.
Background on the Condition
DFNB9 is a rare genetic disorder caused by biallelic mutations in the OTOF gene. This gene provides instructions for producing otoferlin, a protein required for hair cells in the inner ear to transmit sound signals to the brain.
The condition affects approximately 50 children born each year in the United States.
The Gene Therapy Mechanism
Both the clinical trial and the FDA-approved therapy use a viral vector, specifically an adenovirus, to deliver a functional copy of the OTOF gene into the inner ear. The treatment is administered via a surgical procedure.
Once delivered, the gene enables the production of the otoferlin protein, restoring the ability of hair cells to transmit sound signals.
Clinical Trial Findings
A study published by researchers at Mass Eye and Ear involved 42 children and adults born with DFNB9. According to the study report, approximately 90% of patients showed improvement in hearing.
- Patients began to hear within weeks, with hearing continuing to improve for about six months.
- For many patients, hearing quality reached near-normal levels.
- Some patients have maintained improved hearing for over two years.
The study is the largest and longest to date evaluating a gene therapy for hearing loss. The results confirm and extend findings from a smaller study published two years ago. Based on current data, the treatment appears safe, though longer-term follow-up is planned.
FDA Approval and Treatment Details
The FDA has approved a gene therapy developed by Regeneron Pharmaceuticals for patients with OTOF-related deafness.
The approval is based on data from 20 patients, of which 80% showed significant hearing restoration and 42% achieved normal hearing levels.
Regeneron has announced it will provide the therapy at no cost in the United States and expects availability within weeks.
Broader Context
This therapy could potentially become the first FDA-approved gene therapy for deafness. Similar gene therapies for other forms of genetic deafness are being tested by other research groups.
The success of the OTOF gene therapy has prompted researchers to explore similar approaches for other rare forms of genetic deafness and has sparked interest in potential clinical trials for more common forms of hearing loss.
Some members of the Deaf community have expressed concern that medical interventions to restore hearing may stigmatize deafness as a condition requiring a cure.